| Date | Title | Description |
| 21.08.2024 | Preservation Bio's Novel Additive Enables Long-Term Platelet Storage in Refrigeration, with the Potential to Address Major National Blood Supply Challenge | With U.S. Blood Donations at a 20-Year Low, New Research Published in the Journal Blood Demonstrates How the Additive Could Extend Platelet Storage to 14 Days, Significantly Reducing Contamination Risk and Waste
CINCINNATI, Aug. 21, 2024 /P... |
| 27.07.2024 | Bridging the Gap: The New Era of Biotech Innovation in Chicago | In the heart of Chicago, a new partnership is blossoming. Orange Grove Bio and the University of Chicago have joined forces. Their mission? To transform groundbreaking research into real-world solutions. This collaboration is more than just... |
| 23.07.2024 | Orange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and Commercialization | Collaboration Aims to Bridge the Gap Between Academic Research and Commercial Development, Fostering a Thriving Biotech Ecosystem in Chicago
CINCINNATI, July 23, 2024 /PRNewswire/ -- Orange Grove Bio, a leading integrated biopharmaceutical ... |
| 09.04.2024 | Temasek-backed Chinese biotech firm D3 Bio raises $62m in Series A+ round | D3 Bio, a global, clinical-stage biotech company that counts Singapore’s Temasek Holdings and Boyu Capital among its investors, has closed a $62-million Series A+ round of financing to advance its pipeline of cancer drugs. |
| 19.01.2023 | Shanghai-based Biotech firm IASO Bio raises USD 75 million in Series C1 funding | NANJING, China, and SHANGHAI, China, as well as SAN JOSE, California, Jan. 17, 2023 — IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical business focused on finding, developing, and manufacturing breakthrough cell treatment... |
| 26.08.2021 | A biotech startup’s hunt for elusive disease targets scores $60M for drug R&D | In the search for new drugs, much of the low-hanging fruit has been picked. But there’s still bounty to be found and Atavistik Bio aims to uncover it by looking in uncharted places. Though still in its infancy, the promise of its technology... |
| 25.08.2021 | Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise | PharmaCyte Biotech, Inc. announced that the Company will expand its product pipeline to again include its diabetes program and its malignant ascites program. Expanding the product pipeline was made possible after PharmaCyte closed on two pu... |
| 25.08.2021 | PharmaCyte Biotech : Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise | PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announce... |
| 12.08.2021 | PharmaCyte Biotech Announces Closing of $15-Million Public Offering | PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announce... |
| 10.08.2021 | PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering | PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announce... |
| 01.07.2021 | Novalis Biotech closes second fund on €25M | Early-stage investor Novalis Biotech has closed its second Biotech Acceleration Fund on €25 million. The vehicle will be used to back startups and scale-up companies reshaping healthcare with technologies such as bioinformatics and genomics... |
| 16.05.2021 | Biotech Company Nuvalent Raises $135 Million | Nuvalent — a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer — announced recently that it completed a $135 million Series B round of funding. These are the details.
Nuvalent — a bio... |
| 07.05.2021 | Big names invest $4M in Chicago biotech startup | - |
| 30.04.2021 | China Digest: Zonsen Biotech bags $34m; 6cloud raises $23m | Zonsen Peplib Biotech has secured 220 million yuan ($34 million) in a Series A+ round of financing, while 6cloud Tech has raised 150 million yuan ($23 million) in a Series C round of financing from Ying Capital, and others. Zonsen Biotech b... |
| 29.04.2021 | China’s Kelun Biotech nets over $77m funding led by CMC-SDIC Capital | Kelun Biotech, a subsidiary of Shenzhen-listed Kelun Pharmaceutical, has secured over 500 million yuan ($77 million) in fresh funding led by CMC-SDIC Capital, a fund co-launched by state-backed China Merchants Capital and SDIC, the lead inv... |
| 05.04.2021 | Bioheng Biotech Raises $80M in Series B Financing | Bioheng Biotech Co., Ltd., a Nanjing, China-based clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, raised $80m in Series B financing.
The round was co-led by GL Ventures, the venture capi... |
| 25.03.2021 | Jack Ma, Sequoia China-backed biotech firm Brii Bio raises $155m in Series C round | Brii Biosciences (Brii Bio), a multi-national innovative therapies developer with operations in both China and the US, has raised $155 million in a Series C round of financing ahead of a potential listing in Hong Kong.
The new financing was... |
| 24.03.2021 | Rossari Biotech slips 3%; co raises ₹300 cr through preferential allotment | The shares of Rossari Biotech Limited slipped over 3 per cent intraday on Wednesday owing to general weakness in the market and on profit-booking. The company’s Board of Directors has approved the issuance of 30.12 lakh equity shares on a p... |
| 21.03.2021 | Zaara Biotech bags $10 million investment from UAE firm | The startup focuses on research in energy and food crisis
A student biotech startup fostered under the Innovation and Entrepreneurship Development Centre scheme of Kerala Startup Mission has bagged an investment of $10 million from the UAE-... |
| 21.03.2021 | Indian startup Zaara Biotech gets $10 mn investment from UAE’s TCN International | Indian startup Zaara Biotech gets $10 mn investment from UAE’s TCN InternationaliStockphoto 1 min read . Updated: 21 Mar 2021, 02:30 PM IST Rajendra Saxena
Zaara Biotech has received the funding for its project AlgaeSeaweed Technology |
| 11.03.2021 | PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercializa... | FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary... |
| 11.02.2021 | Cancer biotech Cyteir raises $80M, plans to double headcount this year | Lexington biotech Cyteir Therapeutics, a startup whose method of fighting cancer involves an approach called "synthetic lethality" that blocks cancer cells' ability to repair themselves, has brought in $80 million in Series C fina... |
| 29.01.2021 | Swiss-US biotech secures 5 million USD to advance pipeline | Cellvie, a leader in Therapeutic Mitochondria Transfer (TMT), was founded by James McCully, Alexander Schueller (CEO), Pedro del Nido and Sitaram Emani in 2018. Mitochondria are the powerhouses of the cell, generating most of the cellular e... |
| 13.01.2021 | Biotech startup raises $25M for cancer, Covid-19 vaccines | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 12.01.2021 | Runway Growth Capital Announces a Senior Secured Term Loan of $50 Million to VERO Biotech | |
| 12.01.2021 | Biotech startup launches with $110M | Atalanta Therapeutics, a Boston-based developer of treatments for neurodegenerative diseases, has launched with a $110 million Series A from F-Prime Capital. The startup has also teamed up with fellow biotech companies Biogen and Genentech ... |
| 18.12.2020 | China’s healthcare-focused LYFE Capital leads $92m funding in biotech firm ABclonal | ABclonal Technology, a US-based provider of customised biology research reagents and services, announced on Friday that it has closed 600 million yuan ($91.8 million) in a Series C round of financing led by healthcare-focused investor LYFE ... |
| 13.12.2020 | American biotech Kraig Biocraft Laboratories secures US$ 950,000 bridge financing | - |
| 18.11.2020 | Chinese biotech startup D3 Bio raises $200m in Series A round | Chinese biotech startup D3 Bio, a precision medicine developer, has closed its Series A funding round at $200 million to support the development of the firm’s portfolio in oncology and immunology.
Chinese private equity firm Boyu Capital, M... |
| 18.11.2020 | Chinese biotech startup D3 Bio raises $200m in Series A round | Premium
Chinese biotech startup D3 Bio, a precision medicine developer, has closed its Series A funding round at $200 million to support the development of the firm’s portfolio in oncology and immunology.
Continue reading this story with a ... |
| 06.10.2020 | Biotech looking to fight kidney disease launches with $51 million | A Cambridge biotech that’s working on drugs to reverse kidney disease — rather than merely slow its progression ― was unveiled Tuesday after raising $51 million in venture capital.
Walden Biosciences was created by Chicago-based ARCH Ventur... |
| 09.09.2020 | China Digest: Hrain Biotech raises $29m Series B+; Qiming leads new funding in Weier | Premium
Hrain Biotechnology has pocketed 200 million yuan ($29 million) in a Series B+ round, while Weier Technology has raised “tens of millions of US dollars” in a Series B round led by Qiming Venture Partners.
Continue reading this story... |
| 28.08.2020 | Fortress Biotech takes out $60M loan for debt purposes; Entasis pulls in $25M private placement for PhIII trial | Fortress Biotech, the incubator at the center of a stock market scandal two summers ago, is taking out a loan to refinance existing debt.
The company is borrowing $60 million through Oaktree Capital Management, with th... |
| 25.08.2020 | Madison biotech company using $10M in recent funding to build therapeutics | A Madison biotechnology company is applying $10 million in recently raised capital to build out its manufacturing capacity for its product – therapeutics that repair human tissue.
Vascugen Inc., founded in 2017, is developing regenerative m... |
| 22.06.2020 | Biotech Progenity raises $100 million in initial public stock offering, shares fall | Progenity, a biotechnology company focused on precision medicine and testing for genetic diseases, became San Diego’s latest publicly traded company on Friday, raising $100 million in an initial public stock offering.
The company sold 6.8 m... |
| 03.06.2020 | Bullish biotech market propels Pliant to $144M IPO — as Novartis provides a $10M boost | After pharma partner Novartis boosted its IPO with a $10 million private placement, Pliant Therapeutics has wrapped its journey to the Nasdaq on a high note.
Bernard Coulie
Pliant had penciled in a $86 million raise back i... |
| 01.06.2020 | Md. biotech lands $628M contract to accelerate Covid-19 vaccines | Editor’s Note: This story first appeared in the Washington Business Journal. See the original post here.
Emergent BioSolutions Inc. has been doubling down on Covid-19 vaccines and treatments. Now, the federal government is betting on the Ma... |
| 26.05.2020 | After years of partnerships, AI biotech Exscientia lands first major financing round at $60M | After years racking up partnerships with biotechs and Big Pharma, the AI drug developer Exscientia has landed its first large financing round.
The UK-based company raised $60 million in a Series C round led by Novo Holdi... |
| 05.05.2020 | Singapore biotech startup RWDC bags USD 133 million in Series B | Singapore-based biotech startup RWDC Industries, producer of biodegradable material, on Tuesday announced the closing of a USD 133 million two-stage Series B funding round.
“We are grateful and excited to have the support of world-class inv... |
| 03.04.2020 | Legend Biotech raises $150.5m in equity financing at $1.95b valuation | Premium
Legend Biotech Corporation, the majority-owned cell therapy arm of Hong Kong-based life science firm Genscript Biotech, has entered into an agreement to raise about $150.5 million, according to a regulatory filing with the Hong Kong... |
| 02.03.2020 | Cancer biotech gets another new name (now it’s called Xilio) and more than $100 million | For the second time in less than two years, Akrevia Therapeutics has changed its name, in conjunction with the news that it has raised more than $100 million in additional venture capital.
The biotech, based in Waltham, Mass., is trying to ... |
| 25.02.2020 | China Digest: GGV leads $14m in Rongyisuan; Hugo Biotech raises funding | Premium
GGV Capital has led a Series A+ round of nearly 100 million yuan ($14 million) in Chinese tax and accounting startup Rongyisuan, while Beijing-based Hugo Biotech has also raised almost 100 million yuan ($14 million) in its first fun... |
| 20.01.2020 | French biotech Seekyo raises €800,000 to test its tumor-targeting smart chemotherapy | Seekyo, a Poitiers-based biotech startup developing new chemotherapies, has raised €800,000 in seed funding to validate its flagship tumor-targeting drug.
The financing consists of €400,000 from angel investors in the BAdGE, Investessor, an... |
| 18.12.2019 | ARCH-backed biotech emerges with $85M and a bold claim: A new human hormone can reverse a key effect of aging | The elderly patient’s muscles didn’t look right beneath the microscope.
Russ Cox
He wasn’t just old. He had diabetic myopathy, a complication where muscles degrade faster than normal. The mitochondria die, fibers weake... |
| 09.12.2019 | Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status | → Zentalis Pharmaceuticals just nabbed an $85 million round from a syndicate that includes Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital and Even... |
| 02.12.2019 | Biotech Company Raises $14M Nearly a Year After Moving to ATL | Nearly a year after a California biotech company moved its headquarters to Cobb County, the firm has raised more than $14 million in a funding round.
BioIQ raised about $14 million in equity from 12 investors, according to a filing with the... |
| 26.11.2019 | With momentum from FDA OK, SK Biopharma to breath new life into Korean biotech with $850M IPO — report | SK Life Science’s recent success at the FDA is setting its parent company nicely for a $850 million IPO in Korea, the Financial Times reported.
The group — a subsidiary of the conglomerate SK Holdings dedicated to drug... |
| 20.11.2019 | IFA Fund invests $4 million in Telluris Biotech India | The biotech firm looks to protect crops and enhance yield.
The Innovation in Food and Agriculture Fund (IFA Fund) has committed investment up to $4 million for a minority holding in Hyderabad-based Telluris Biotech India Private Limited.
Te... |
| 14.11.2019 | Pincer movement: California biotech gets $35M to suffocate cancer in coordinated attack | Having served in Afghanistan, the navy veteran leading California-based EpicentRx wants to leave no patient behind with his arsenal of anti-cancer drugs. On Thursday, the company was given a $35 million boost to further... |
| 07.11.2019 | A Biotech Company Gets $100M For The Future of Pig-To-Human Transplants | 23 Shares Email Facebook Twitter LinkedIn
There are nearly 2 million people on the organ transplant waiting list around the world. Some of the original CRISPR – a modern, advanced gene editing tool – engineers think that pig organs could be... |
| 30.10.2019 | Matrix-backed Chinese biotech startup Genecast closes $43m Series D1 round | Premium
Genecast Biotechnology, a Chinese biotech startup that specialises in next-generation sequencing (NGS) technology and bioinformatics, has raised 300 million yuan ($43 million) in a Series D1 round of financing led by CICC Capital, a... |
| 04.10.2019 | UChicago Biotech Startup Raises $2M to Develop Feces Biosensors | A Chicago startup with roots at the University of Chicago just raised its first round of funding as it works to develop a better way to detect harmful bacteria in your poop.
BiomeSense announced Thursday that it raised $2 million in a seed ... |
| 24.09.2019 | Quiet biotech Amphivena nabs $62M funding round
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Little-known and super quiet biotech Amphivena Therapeutics has grabbed a strong and healthy $62 million series C round funding haul.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Central for one scient... |
| 23.09.2019 | Deepening US footprint, AstraZeneca-partnered French biotech Innate shoots for $100M IPO | Fresh off of a 20th birthday celebration, French biotech Innate Pharma filed for a US IPO worth up to $100 million. They detailed in their filings a strategy to roll cash into preclinical work, advancing the trials for two... |
| 11.09.2019 | IU invests $500,000 in Richard DiMarchi’s latest biotech startup | - |
| 23.08.2019 | Canadian biotech company Chinook Therapeutics raises $65M for rare kidney disease therapies | Chinook Therapeutics CEO Eric Dobmeier. (Chinook Photo)
Chinook Therapeutics, a Vancouver, B.C.-based biotech company creating targeted therapies for kidney diseases, raised $65 million in a Series A financing round led by Versant Ventures ... |
| 26.07.2019 | Jupiter biotech scores $56M to defeat herpes, in a field littered with failure | Scientists have repeatedly stumbled in their quest to develop a herpes vaccine. Jupiter, Florida-based biotech X-Vax Technology thinks it may have the formula — and now has $56 million in the bank to prove it.
Infection w... |
| 25.07.2019 | A 2-year-old fledgling biotech steers into PhIII and nabs a quick $565M buyout deal | Aldo Iacono University of Maryland
A biotech startup in Europe with a very careful focus on a single Phase III therapy has quickly parlayed a drug/device play for a rare lung disease into a $565 million buyout deal.
The ... |
| 23.07.2019 | Chinese biotech startup raises USD 20 million to grow human tissue and organs in pigs | Qihan Biotech, a startup focusing on developing so-called xenotransplantation technology, closed a USD 20 million funding round with CMB International and Legendstar, according to 36Kr.
The xenotransplantation technology the firm is working... |
| 19.06.2019 | Belgium-based biotech startup Imcyse secures €35M Series B funding, a hope to patients with chronic diabetes | Imcyse, a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases, recently announced that it has raised €35 million ($39.5M) in a Series B financing round and through other channels.
The fin... |
| 30.05.2019 | Houston biotech company closes $120M Series B, Chevron taps local startup for program, and more innovation news | Big things are happening in Houston — from a $120 million close to the U.S. Department of Energy picking a Houston-area company for nuclear energy research. Here are the highlights of Houston innovation news you might have missed.
Need more... |
| 26.04.2019 | Nine listings and $3.8B later, HKEX celebrates one-year biotech anniversary with $194M CRO IPO | So how is Hong Kong stock exchange’s biotech board doing one year after regulators opened up the listing regime to pre-revenue companies in the field?
Depends on how you look at it.
Charles Li
While only nine biotech companies... |
| 17.04.2019 | Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s | For the past 8 years or so Bruce Bean and Clifford Woolf at Harvard and Boston Children’s have been laboring in the lab to demonstrate how you could inhibit pain and itch signaling in a targeted set of neurons. And now a VC syn... |
| 10.04.2019 | Lynparza secures third EU nod; Protein degradation biotech grabs $16M launch round from Chinese VCs; Wave shares tumble on trial delay | → Lynparza, the first PARP inhibitor from AstraZeneca $AZN to win US approval in 2014, has secured its third EU approval. The drug won the EMA nod for use patients with germline BRCA1/2-mutations and who have human epidermal gr... |
| 03.04.2019 | Belgian biotech founded by University of Torino team nabs $23.5 million in Series A round | Having spent more than two decades researching biology of the hepatocyte growth factor (HGF), Paolo Michieli and his team at the University of Torino, Italy forged a collaboration with Netherlands-based biotech Argenyx t... |
| 01.04.2019 | Pfizer biotech spinout nabs $125M megaround as Bain-backed syndicate bets on its late-stage game plan | SpringWorks Therapeutics launched in the fall of 2017 with a whopping $103 million round and some well-developed Pfizer assets that the company had high hopes for. And now Bain, Pfizer and the rest of the founding investors h... |
| 18.03.2019 | Biotech startup raises $68 million to further work on its treatment for schizophrenia | Karuna Therapeutics, a Boston-based biotech startup, said Monday it has raised $68 million in venture capital to advance clinical development of a radically different drug for schizophrenia.
The sum is on top of $42 million that Karuna, a p... |
| 26.10.2018 | Novo-backed Galecto Biotech scores €79 million in Series C funding | Galecto Biotech has closed a €79 million Series C funding round that will help advance the development of its lead galectin-3 inhibitor for idiopathic pulmonary fibrosis (IPF).
Hans Schambye
The Copenhagen-based company, ... |
| 02.10.2018 | Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO | Arie Belldegrun and David Chang are thinking big again, of course.
Today the pair running the biotech startup Allogene, a CAR-T company $ALLO looking to make history pioneering off-the-shelf cell therapeutics, outlined p... |
| 24.09.2018 | UChicago Biotech Startup Gets $2.3M From NIH, Makes MassChallenge Finals | Chicago biotech company Oxalo Therapeutics, which is developing a drug to treat and prevent kidney stones, has made it to the final round of a high-profile startup accelerator competition while also picking up some new funding to grow.
Oxal... |
| 10.09.2018 | Circled by rival pharma giants and a biotech powerhouse, Kodiak asks for a $100M-plus IPO for new eye drug | Kodiak Sciences was never one of those biotechs that liked to tout every financing round or talk up its drug prospects. Helmed by biotech vet and former MPM venture partner Victor Perlroth, it turns out the biotech has been stead... |
| 15.08.2018 | Biotech startup Paragen Bio raises $6 million for its work fighting diseases with parasitic worms | Professor Alex Loukas, co-founder and head of research at Paragen Bio. Source: Romy Bullerjahn.
Queensland biotech startup Paragen Bio has launched in spectacular fashion with an initial $6 million investment to continue developing new trea... |
| 25.07.2018 | Industrial Biotech Company Jennewein Biotechnologie Receives €15M from EIB | Jennewein Biotechnologie GmbH, a Rheinbreitbach, Germany-based industrial biotechnology company, received €15m in financing.
The European Investment Bank (EIB) provided the financing. The EU bank’s loan is backed by a guarantee from the Eur... |
| 12.07.2018 | Biotech Company Mitra RxDx Raises $40M in Financing | Mitra RxDx (dba Mitra Biotech), a Boston, MA-based biotech company and global leader in advancing personalized oncology treatment, completed a $40m financing round.
The round, which brings cumulative funding to date to $76m, was led by Nort... |
| 29.06.2018 | Chinese biotech startup I-Mab raises $220m Series C led by Hony Capital | Premium
Chinese biotechnology startup I-Mab Biopharma has raised $220 million in a Series C round led by Hony Capital and joined by Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, Singapore-based EDBI, as well as exi... |
| 13.06.2018 | Biotech startup lands $1.8 million in funding | - |
| 24.05.2018 | Autoimmune biotech Kiniksa prices upsized $152M IPO as Scholar Rock bags $75M for preclinical SMA drug | Two biotechs that have been on parallel IPO tracks are blasting off with sizable support for their Nasdaq debuts.
Kiniksa got the bulkier raise among the two, reaping $152 million at $18 a share — up from the $126 million it was ... |
| 01.03.2018 | US biotech firm Viela Bio raises $250m in Temasek-backed Series A | Premium
US-headquartered Viela Bio, an inflammation and autoimmune biotech spinout of AstraZeneca, has raised $250 million in Series A funding backed by Singapore state-owned investment firm Temasek.
Continue reading this story with a subsc... |
| 16.01.2018 | China biotech unicorn Innovent in talks on $200M IPO and new funding — report | A little more than a year ago, Shanghai-based Innovent Biologics raised a record $260 million D round for its efforts to lead the first biosimilar wave in China. Now, they are taking the next step and planning an IPO that could... |
| 05.12.2017 | Feeling blue? Biotech startup raises $13M to create ‘natural’ color pigments using algae | Lumen Biosciences co-founder and CEO Brian Finrow. (Lumen Photo)
We all love a splash of color in our lives, but we seldom realize the technology that goes into the dye in a favorite sweater or the precise coloring in a set of makeup. It tu... |
| 29.11.2017 | Biotech startup scores $20M to develop drug that triggers the immune system to fight cancer | (Shutterstock Photo)
Mavupharma, a biotech startup based in Kirkland, Wash., announced Wednesday that it has raised a $20 million Series A funding round to develop a unique class of drug that enables the body’s immune system to fight cancer... |
| 08.11.2017 | German biotech InflaRx raises $100M in IPO | InflaRx, a German biopharma developing drugs for rare diseases, has raised $100 million in the industry’s third IPO this month.
The company sold 6.7 million shares at $15, the midpoint of their $14 to $16 range. Insiders sn... |
| 26.09.2017 | Newly debuted biotech shoots for $40M IPO; Intellia touts new animal data on CRISPR/Cas9 | ⇨ Just 8 months after making its debut at the beginning of the year, Cambridge, MA-based Cue Biopharma has filed for a $40 million IPO. The TCR company is based on work done at Albert Einstein College of Medicine. The biotec... |
| 21.09.2017 | A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up | Samantha Du
Zai Lab CEO Samantha Du is scheduled to step up and ring the opening bell on Nasdaq this morning — and she’ll have plenty to cheer about.
The Shanghai-based biotech raised $150 million from its upsized IPO on Wednesda... |
| 21.09.2017 | First biotech emerges from Garabedian’s accelerator armed with $10M, plans to tackle autoimmune diseases | Chris Garabedian’s accelerator has spawned its first biotech. The startup, Landos Biopharma, has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million from Perceptive Advisors to take a LANCL2-targeted treatment for inflamma... |
| 17.09.2017 | Closing in on another mega-raise, UK biotech star Immunocore grabs $40M investment from Gates Foundation | Immunocore CEO Eliot Forster
As reports circulate that the British biotech star Immunocore is in the final leg of pulling together another mega-raise, the executive crew at the TCR company has lined itself up for a $40 mil... |
| 05.09.2017 | Cancer vax biotech Amal grabs $10M round; Global Blood Therapeutics eyes PRV with new FDA designation | ⇨ Geneva-based Amal Therapeutics has picked up about $10 million in Series B money for its work on peptide-based cancer vaccines. Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund invested alo... |
| 10.08.2017 | Zimmer BioTech Raises €7M in Funding | Zimmer BioTech, a Neu-Ulm, Germany-based drug development startup, raised €7m in funding.
Backers included Zimmer MedizinSysteme GmbH, the medical device producer which spun off the company, and High-Tech Gründerfonds.
The company will use ... |
| 07.07.2017 | Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round | George Elston, 2X Oncology
⇨ A Cambridge, MA-based startup named 2X Oncology has in-licensed a mid-stage PARP inhibitor from Eisai. A spin-out of Oncology Venture, their web site says new CEO George Elston is working with ... |
| 22.06.2017 | Celgene-backed cancer biotech Repare emerges from stealth with $68M
W h i t e p a p e r
Weighing the Costs: | After 18 months being incubated by Versant Ventures, upstart Repare Therapeutics has emerged from stealth mode with an impressive $68 million, backing from Celgene and some big-name execs.
Sponsored by Agilent Technologies
How would you lik... |
| 06.06.2017 | Australia: Brandon Capital, Uniseed invest $16m in biotech startup QUE | Premium
Australian venture capital firms Brandon Capital and Uniseed have invested up to $16 million in clinical-stage biotechnology startup QUE Oncology Inc.
Continue reading this story with a subscription to DealStreetAsia.
Subscribe
Alre... |
| 25.05.2017 | Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal | Yutaka Niihara
A little-known biotech out of Torrance, CA is one big step closer to winning the first new drug approval for sickle cell disease in close to 20 years. And it has achieved precious little attention for its years-... |
| 17.05.2017 | G1 Therapeutics joins a growing biotech winners circle with $105M IPO | Mark Velleca
G1 Therapeutics is now the latest in a string of biotech IPOs to start out with a hit on its price range. The Research Triangle Park, NC-based outfit raised $105 million by selling 7 million shares at $15 each. Tha... |
| 15.05.2017 | Durham-based Biotech Know Bio Raises $2.6 Million | A Durham, North Carolina-based biotechnology company raised more than $2.6 million in a private equity offering, according to a filing Friday with the Securities and Exchange Commission.
Know Bio LLC raised the money from 43 investors, acco... |
| 15.05.2017 | Durham-based Biotech Know Bio Raises $2.6 Million | A Durham, North Carolina-based biotechnology company raised more than $2.6 million in a private equity offering, according to a filing Friday with the Securities and Exchange Commission.
Know Bio LLC raised the money from 43 investors, acco... |
| 08.03.2017 | Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition | Jens Stegemann, CEO
The German aerosol therapy company PARI Pharmaceuticals is spinning out a Phase III effort to develop a drug/device combo that matches an inhaled formulation of an immunosuppressant with a remot... |
| 01.02.2017 | Cellestia Biotech raises CHF 8 million seed financing | Cellestia Biotech raises CHF 8 million seed financing 01.02.2017 09:00, Anne-Lea Marte linkedIn facebook twitter instagram youtube -->
Cellestia Biotech AG, a private biopharmaceutical company with strategic focus on anti-cancer drugs mo... |
| 07.10.2016 | Local Biotech Kurin Inc. Raises $2.3 Million in Equity Funding | Local biotech Kurin Inc. has reported raising $2.3 million in an equity offering launched Sept. 23.
In an Oct. 7 filing with the U.S. Securities and Exchange Commission, the firm said a total of 28 investors chipped in to the round. The mon... |
| 27.09.2016 | Cancer biotech upstart grabs $18M round, sets out to master relapsed prostate cancer | Jay Lichter
UC San Francisco researcher Bin Liu has spent years in the lab studying how to tackle prostate cancer cells. Recently, he’s been making progress on a new receptor target that he believes can come into play as pati... |
| 29.08.2016 | Mitra Biotech raises $27.4 mn from Sequoia, Sands Capital, others | Mitra Biotech Pvt. Ltd, which focuses on personalised cancer care and rational drug development, has raised $27.4 million in a Series B round of funding co-led by Sequoia India and Washington-based Sands Capital Ventures, it said in a state... |
